Will drugs companies follow EU agency from London to Amsterdam?

Financial Times

16 May 2019 - Amid the bustling skyscrapers of London’s Canary Wharf, one building stands silent and shuttered — a concrete symbol of the cost of Brexit.

A lone security guard still sits behind the reception desk beneath the logo of the European Medicines Agency, but the revolving doors through which scientists from around the world once streamed to discuss transformative new medicines are firmly locked.

The EMA decamped to new premises in Amsterdam at the beginning of March, a shift that became inevitable from the moment the EU referendum result was announced in the small hours of 24 June 2016.

Read Financial Times article

Michael Wonder

Posted by:

Michael Wonder